Banff, Alberta—New research indicates that the novel agent eluxadoline is effective for treating abdominal pain in patients with diarrhea-predominant irritable bowel syndrome who have previously responded inadequately to loperamide.
The international, multicenter team behind the study reported that a significantly greater percentage of patients treated with eluxadoline (Viberzi, Allergan) experienced improvements in abdominal pain relative to placebo over the 12-week treatment period.